LYEL · ISSUER CIK 1806952
Lyell Immunopharma, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 6 Lyell Immunopharma, Inc. insiders reported $0.00 of open-market purchases and $215K of sales on SEC Form 4.
↗6 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 0 of 9 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$215KInsider selling
−$215KNet open-market
Oct 13, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 13, 202617:17 | Oct 12, 2026 | LYEL | Chief Medical Officer | S · Sell | $8.63 | −422 | 19,857 | -2% | −$4K | ||
| Sep 10, 202619:37 | Sep 10, 2026 | LYEL | Chief Medical Officer | S · Sell | $12.70 | −500 | 20,423 | -2% | −$6K | ||
| Aug 25, 202616:06 | Aug 21, 2026 | LYEL | President and CEO, Director | S · Sell | $15.54 | −9,589 | 63,899 | -13% | −$149K | ||
| Aug 25, 202616:05 | Aug 21, 2026 | LYEL | Chief Operating Officer | S · Sell | $15.54 | −989 | 16,816 | -6% | −$15K | ||
| Aug 25, 202616:03 | Aug 21, 2026 | LYEL | Chief Scientific Officer | S · Sell | $15.54 | −1,457 | 16,220 | -8% | −$23K | ||
| Aug 11, 202616:21 | Aug 10, 2026 | LYEL | VP, Corporate Controller | S · Sell | $14.34 | −621 | 14,799 | -4% | −$9K | ||
| Aug 11, 202616:20 | Aug 10, 2026 | LYEL | Chief Scientific Officer | S · Sell | $14.34 | −131 | 17,677 | -1% | −$2K | ||
| Aug 11, 202616:18 | Aug 10, 2026 | LYEL | Chief Operating Officer | S · Sell | $14.34 | −89 | 17,805 | -0% | −$1K | ||
| Aug 11, 202616:07 | Aug 10, 2026 | LYEL | President and CEO, Director | S · Sell | $14.34 | −390 | 73,488 | -1% | −$6K |